Allogene, Stanford to Develop Better CAR-T Therapies
Allogene Therapeutics inked a research collaboration deal with Stanford University to work on a novel nucleic acid delivery system for CAR-T therapy.
Lilly's Targeted RET Drug Shrinks Tumors In Lung Cancer Clinical Trial
Pfizer Posts 30 Percent Rise In Quarterly Profit
Oklahoma Judge Approves Teva's $85 Million Opioid Settlement
Sanofi To Pay Lexicon $260 Million For Terminated Partnership
Mylan Reaches $30 Million Settlement In SEC's EpiPen Probe
FDA Approves Botox For Pediatric Patients With Upper Limb Spasticity
AstraZeneca's Imfinzi Prolongs Survival In Aggressive Lung Cancer
Janssen's Erleada Approved For New Prostate Cancer Indication
Exclusive: CVS to cover migraine drugs from Teva, Lilly; excludes Amgen
Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.
GSK's OTC Nicotine Oral Spray Gets FDA Panel Backing
Endo Submits BLA To FDA For CCH In Patients With Cellulite
Lundbeck and Otsuka's antipsychotic drug Rexulti fails two bipolar late-stage studies
FDA Approves AbbVie's Rinvoq, Potential Successor To Humira
Amgen Drug Shrinks Lung Cancer Tumors In Half Of Patients: Study
Lilly Receives U.S. FDA Approval For Taltz For Treatment Of Active Ankylosing Spondylitis
Amicus Therapeutics' Gene Therapy For Rare, Fatal Childhood Disease Shows Promise In Study
Allergan Beats Q2 2019 Profit; Raises Full-Year Revenue Forecast On Restasis, Juvederm Demand
Bayer Buys BlueRock In $600 Million Bet On Stem Cell Therapies
EU Approves Sanofi, Regeneron's Dupixent For Adolescent Eczema Cases
FDA Panel Backs Gilead's HIV Prevention Drug Descovy, Except In Women
Roche Bid To Recycle Gazyva For Lupus Nephritis Wins FDA Breakthrough Tag
Biogen Scraps Two Late-Stage Trials For Alzheimer's Treatment Elenbecestat
Sosei, Takeda Ink $1.2+ Billion Deal To Develop GPCR Targets
FDA approves Dr. Reddy’s Tosymra
FDA Approves Boehringer Ingelheim’s Ofev In Patients With Sclerosis-Associated Lung Disease
Seattle Genetics, Astellas Drug Rapidly Shrinks Tumors In Bladder Cancer Study
Out From Under Novartis, Alcon Is Its Own Company Now
Ireland Demands $1.9 Billion In Back Taxes From Perrigo
FDA Greenlights Alexion’s Soliris For Rare Autoimmune Disease
FTC loses Shire appeal, losing round in fight against citizen petition abuse
Merck’s Pifeltro, Delstrigo Receive FDA Approval For Virologically Suppressed Adults With HIV-1
Novartis Halts Distribution Of Company’s Zantac Versions Amid Probe Into Impurities
Bristol-Myers Releases Mixed Opdivo Lung Cancer Results
FDA approves Novo Nordisk's Rybelsus as first oral GLP-1 receptor agonist for type 2 diabetes
Ad Right Top
Latest News
FDA approves Novo Nordisk’s oral diabetes drug
The U.S. Food and Drug Administration approved Novo Nordisk's Rybelsus (semaglutide) tablets 7 mg or 14 mg for adults with type 2 diabetes that along with diet and exercise may improve blood sugar.
French weight-loss pill scandal set for landmark trial
A landmark French trial will seek to settle one of the country’s biggest pharmaceutical scandals, probing whether the company behind a weight-loss drug believed to have triggered killer side effects covered up the risks.
MedAdNews
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com. 
August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!